Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring COVID-19 in Healthcare Workers (COVID-19)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04535791 |
|
Recruitment Status :
Completed
First Posted : September 2, 2020
Last Update Posted : December 22, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
In a blinded randomized clinical trial, which will include health workers (doctors, residents, nurses, stretcher-bearers, technicians, hygiene and cleaning) who are members of the health teams that care for patients with COVID-19. Two groups will be formed: the Vitamin D group taking 4,000 IU orally daily for 30 days, the control group being given a placebo during the same time period.
Participants will be adults, who have not had COVID-19 disease, and who sign the informed consent. At the beginning of the study anthropometric variables (weight, height, BMI) will be taken, the short medical history can be identified to identify comorbidities, and a fasting blood sample will be taken to determine changes in Vitamin D (25 (OH) Vitamin D), in addition to RT-PCR saliva samples, as well as detection of serum antibodies to determine whether or not they have SARS-CoV-2 disease. Participants will follow each other 45 days. Those with COVID-19 disease will be monitored frequently to determine the course of the disease. At the end of 45 days, new samples will be taken to determine levels of vitamin D and antibodies against SARS-Cov-2.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Covid19 Vitamin D | Drug: Cholecalciferol | Phase 3 |
In a blinded randomized clinical trial, which will include health workers (doctors, residents, nurses, stretcher-bearers, technicians, hygiene and cleaning) who are members of the health teams that care for patients with COVID-19. Participants with a history of having COVID-19 disease or who are consuming vitamin D at that time will be excluded. Through randomization, two groups will be formed: the Vitamin D group taking 4,000 IU orally daily for 30 days, the control group being given a placebo (starch) during the same time period. Participants and researchers will be blinded regarding the maneuver.
At the beginning of the study anthropometric variables (weight, height, BMI) will be taken, the short medical history can be identified to identify comorbidities such as diabetes mellitus, hypertension or obesity, and a fasting blood sample will be taken to determine the changes in Vitamin D (25 (OH) VD), in addition to saliva samples by RT-PCR, as well as detection of antibodies in serum to determine whether or not they have SARS-CoV-2 disease. Participants who test positive for COVID-19 will be eliminated by the RT-PCR test. Participants will follow each other 45 days. Contacted weekly to verify the consumption of the capsules, as well as evaluation of adverse effects of vitamin D. Monitored for suspicious data of COVID-19 and in case of presenting the disease by COVID-19, a study will be carried out to confirm the infection through RT-PCR and will be monitored to determine the course of the disease. At the end of 45 days, new samples will be taken to determine levels of vitamin D and antibodies against SARS-Cov-2.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 321 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Blinded randomized clinical trial |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Masking Description: | To ensure that participants are unaware of the intervention they are receiving, both the capsules containing vitamin D3 and the placebo will be the same. Cholecalciferol (Vitamin D3), 4000UI tablets will be purchased from the MEDIX laboratory (trade name HISTOFIL). The placebo will consist of corn starch, which will be purchased from a supplier, who packages it in a 25 kg bag. As it is a dry product, the supplier guarantees that the corn starch maintains its characteristics for 3 years, as long as it is stored in closed container, in a cool and dry place, free of moisture, dust, insects and rodents. The encapsulation of the placebo and vitamin D3 will be carried out by an external supplier with capsules of the capsugel brand, maintaining quality control to avoid contamination of the product during storage and encapsulation. An external researcher will have a list to which group each subject belongs, without being in contact with the research. |
| Primary Purpose: | Treatment |
| Official Title: | Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring or Evolving Into the Severe Form of COVID-19 in Healthcare Workers Caring for Patients With the Disease. Blinded Randomized Clinical Trial |
| Actual Study Start Date : | July 15, 2020 |
| Actual Primary Completion Date : | December 30, 2020 |
| Actual Study Completion Date : | July 15, 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: cholecalciferol (Vitamin D)
cholecalciferol 4,000 IU orally daily (1 capsule) for 30 days
|
Drug: Cholecalciferol
4,000 IU orally daily for 30 days
Other Name: vitamin D |
|
Placebo Comparator: Starch
Starch 500 mg orally daily (1 capsule) for 30 days
|
Drug: Cholecalciferol
4,000 IU orally daily for 30 days
Other Name: vitamin D |
- Number of Participants with COVID-19 [ Time Frame: 45 days ]cases confirmed by RT-PCR for SARS-CoV-2, or by antibody detection.
- Number of Participants with hospitalization for COVID-19 [ Time Frame: 45 days ]participants who, having developed SARS-CoV-2 infection, require hospitalization for the same condition.
- Serum concentration of 25 (OH) vitamin D [ Time Frame: the beginning and through study completion, an average of 45 days ]Serum concentration of 25 (OH) vitamin D at the beginning and through study completion, an average of 45 days
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Health workers in areas of care for patients with COVI-19
- Adults
- Men and women.
- That they agree to participate in the study by signing the letter of informed consent
Exclusion Criteria:
- Those who know that they have already suffered from COVID-19
- Those who have received a vitamin D supplement in the previous two weeks.
- Difficulty obtaining blood samples
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04535791
| Mexico | |
| Hospital Centro Medico Nacional Siglo XXI | |
| Mexico City, Distrito Federal, Mexico, 06720 | |
| Principal Investigator: | Miguel Angel Villasis-Keever | Coordinación de Investigación en Salud, Mexico |
| Responsible Party: | Miguel Angel Villasis Keever, Clinical Professor, Coordinación de Investigación en Salud, Mexico |
| ClinicalTrials.gov Identifier: | NCT04535791 |
| Other Study ID Numbers: |
R-2020-785-090 |
| First Posted: | September 2, 2020 Key Record Dates |
| Last Update Posted: | December 22, 2021 |
| Last Verified: | December 2021 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
|
COVID-19 Pneumonia, Viral Pneumonia Respiratory Tract Infections Infections Virus Diseases Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections |
Lung Diseases Respiratory Tract Diseases Vitamin D Cholecalciferol Vitamins Micronutrients Physiological Effects of Drugs Bone Density Conservation Agents Calcium-Regulating Hormones and Agents |